

Growth Inhibitory Activities of Kalopanaxsaponins A and I against Human Pathogenic Fungi

Dong-Wook Kim¹, Kyu-Ho Bang², Young-Ha Rhee², Kyung-Tae Lee³ and Hee-Juhn Park⁴

¹Research Institute for Wakan-Yaku, Toyama Medical and Pharmaceutical University 2630, Sugitani, Toyama 930-01, Japan, ²Department of Microbiology, Chungnam National University, Taejon 305-764, ³College of Pharmacy, Kyung-Hee University, Dongdaemun-ku, Seoul, 130-701 and ⁴Department of Botanical Resources, Sangji University, Wonju 220-702, Korea

(Received July 15, 1998)

Antifungal activities of the compounds isolated from *Kalopanax pictus* against representative fungi of dermatomycosis were investigated using paper disc diffusion method. It was found that kalopanaxsaponins A and I were effective in inhibiting the growth of *Candida albicans* KCTC 1940 and *Cryptococcus neoformans* KCTC 7224 with minimum inhibitory concentration (MIC) of 25 µg/ml. It showed that antifungal activity of both compounds have strong selectivity against the fungi of dermatomycosis.

Key words : Kalopanaxsaponin, Antifungal activities, Minimum inhibitory concentration (MIC), Dermatomycosis

INTRODUCTION

The stem bark of *Kalopanax pictus* (Araliaceae) has been used as traditional crude drugs for the treatment of the feeble, neurotic pain, lumbago, various inflammation and especially for diabetesmellitus. A number of natural components have been isolated from this plant (Shao *et al.*, 1989a, b; Sano *et al.*, 1991) and further the effective constituents on liver damage have been reported (Lee *et al.*, 1995). Recently, we have reported the isolation of the active principle reducing hyperglycemia, hypercholesterolemia and hyperlipidemia in the streptozotocin-pretreated rat (Park *et al.*, 1998).

In the continuous biological studies on this plant materials, we investigated the antifungal effects of the compounds isolated from *K. pictus*. Because it is hard to develop antifungal drug compared with that of antibacterials, the developmental tempo on the former is slow. The reason is that many antifungals are toxic to human cell in addition to fungus cell which posed both eucaryotic cell structures. Practically, most synthetic antifungal drugs are showing the side effects such as the toxicities due to long-term administration against kidney and liver, headaches, skin hypersensitivity and endocrinal disorder (Yamaguchi, 1990; Yoo, 1997).

From these point of view, the studies on antifungal substances with little toxicities derived from natural pro-

ducts are progressive by many workers. Most fungal strains used in the reports for natural antifungal substances have been included plant pathogenic fungi, animal pathogenic fungi and rarely human skin fungi as the object of fungal strains. However, we examined the antifungal spectrum mainly against human pathogenic fungi such as three kinds of *dermatophytes*, the representative fungi strains of superficial dermatomycosis, which is classified by Ormby and Montgomery (1954) and clinically important, and two kinds of fungal strains exerting deep dermatomycosis, the representative fungal strains of candidiasis and one fungal strain belonging to *Penicillium* species.

The present paper describes the antifungal activity of the compounds isolated from *Kalopanax pictus* against human pathogenic fungi of dermatomycosis.

MATERIALS AND METHODS

Materials

The experimental materials including liriiodendrin, syringin, kalopanaxsaponin A, B, H and I, were isolated from *Kalopanax pictus* in our previous work (Park *et al.*, 1998), and were used. Structures of *Kalopanaxsaponin* A, B, H and I are shown in Fig. 1. As other materials, hederagenin was obtained from the isolation of total acid hydrolysate of the stem bark of *K. pictus* and ursolic acid (Δ^{12} -ursene-3 β -ol-28-oic acid) is an authentic specimen. The fungal strains used in this experiment are as followings: Superficial dermatomycosis, *Tricophyton*

Correspondence to: Hee-Juhn Park, Department of Botanical Resources, Sangji University, Wonju 220-702, Korea

by the inhibitory zone from the 50 µg/ml to 200 µg/ml conc. against *A. niger*.

The Antifungal activity of Kalopanaxsaponin A and I against *C. albicans* were dose-dependent manner (Fig. 2). However, liriiodendrin, syringin, ursolic acid and hederagenin were inactive. The growth of *C. albicans* and *A. niger* were not inhibited by any concentrations of these compounds.

Among seven compounds used in this test, only kalopanaxsaponin A and I have significant antifungal activities. Triterpenoid saponins, rather than those genins, have been reported to show often antifungal activities. Camellidin I and II which have been isolated from *Camellina japonicus* were reported to have antifungal effects against *Psetalotia longiseta* of plant pathogenic fungi (Ishidate *et al.*, 1953; Nishino *et al.*, 1986). It has been also demonstrated that 3-*O*-glucosides of hederagenin, bayogenin and medicagenic acid of the root of *Dolichos killimanscharicus* (Marston *et al.*, 1988) and sakurasosaponin of the leaves of *Rapanea melanophloes* (Kazuhiro *et al.*, 1993) exhibited anti-




Fig. 2. Inhibitory zones vs. added amounts of kalopanaxsaponins A and I against *C. albicans* KCTC 1940.

fungal effects. However, these effects are biological results against only plant pathogenic fungi. In addition, avenacins (Maizel *et al.*, 1964; Crombie *et al.*, 1984a, b; Grayer *et al.*, 1994) have been reported that the MICs are over the range of 25~50 µg/ml (Maizel *et al.*, 1964) against six kinds of plant pathogenic fungi and animal pathogenic fungi (25 µg/ml against *Tricophyton interdigitale*; 25 µg/ml against *Saccharomyces pastorianus*; 50 µg/ml against *Candida albicans*, *Collectotrichum pisi*, *Endocanidiophora fagacearum* and *Pythium irregulare*). As examined in the literatures, the antifungal report on naturally occurring compounds against human pathogenic fungi was hardly found. Moreover, antifungal principles of *Kalopanax pictus* have never been elucidated.

The antifungal effects of kalopanaxsaponin A and I against the fungal strain occurring human dermatomycosis were illustrated in Table II. The MICs of kalopanaxsaponin A and I were 25 µg/ml to *C. albicans* KCTC 1940 and *C. neoformans* KCTC 7224. This value was estimated to be markedly low when compared with those of other natural antifungal agents, while it is remarkably high compared with those of clotrimazole (positive control) of synthetic antifungal agents. The MIC on *A. niger* occurring human deep dermatomycosis was observed at 200 µg/ml conc.. Antifungal effects on other strains were not observed (>200 µg/ml). This finding suggests that these two saponin compounds were selective to very limited fungal strains.

Although kalopanaxsaponin B and H are also hederagenin glycosides, they showed no activity against the fungi used in this experiment. This finding can be speculated that 28-*O*-glycoside instead of 17-free carboxyl removes the activity, maybe rather than the polarity due to increment of sugar moiety. It can be reminded that very little difference between the effects of kalopanaxsaponin A and I was found though numbers of sugar moiety were different each other. Marston *et al.* (1988) have reported the antifungal activity of hederagenin 3-*O*-glucoside against *Cladosporium cucumerium* of plant pathogenic fungi, while hederagenin and ursolic acid tested exhibited no activity. As examined in the present test results and literature data, it was

Table II. Minimum inhibitory concentration (MIC) of kalopanaxaponins A, B, H and I against various fungi (µg/ml)

| Antifungal agents | KCTC ^a | KCTC ^b | KCTC ^c | KCTC ^d | KCTC ^e | KCTC ^f | KCTC ^g |
|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|
| | 6077 | 1252 | 1246 | 7224 | 1700 | 1940 | 1253 |
| Kalopanaxaponin A | >200 | >200 | >200 | 25.0 | 200 | 25.0 | >200 |
| Kalopanaxaponin B | >200 | >200 | >200 | >200 | >200 | >200 | >200 |
| Kalopanaxaponin I | >200 | >200 | >200 | 25.0 | >200 | 25.0 | >200 |
| Kalopanaxaponin H | >200 | >200 | >200 | >200 | >200 | >200 | >200 |
| Clotrimazole* | 1.22 | 2.44 | 0.61 | 0.61 | 1.22 | 4.88 | 0.61 |

*Positive control

^a*T. mentagrophytes* KCTC 6077, ^b*M. gypseum* KCTC 1252, ^c*E. floccosum* KCTC 1246, ^d*C. neoformans* KCTC 7224, ^e*A. niger* KCTC 1700, ^f*C. albicans* KCTC 1940, ^g*P. avellaneum* KCTC 1253

suggested that glycoside linkage to 3-OH of hederagenin played an important role in the exhibition of the antifungal activity.

It is our interests that kalopanaxaponin A and I exhibited strong and specific antifungal activities to *C. albicans* and *C. neoformans*. On consideration of relatively low toxicity of natural compounds compared to synthetic compounds, these two saponins can be suggested as model compounds effective to candidiasis and the infection of *C. neoformans* of deep dermatomycosis.

ACKNOWLEDGEMENT

We thank Dr. D. H. Kim of Kyung-Hee University for valuable advice in this research.

REFERENCES CITED

- Crombie, L., Crobbie, W. M. L. and Whiting, D. A., Isolation of avenacin A-1, A-2, B-1 and B-2 from oat roots: structure of the four their 'aglycones', the avenestergenins. *J. Chem. Soc. Chem. Commun.*, 244-246 (1984a).
- Crombie, L., Crobbie, W. M. L. and Whiting, D. A., Structure of the four avenacins, oat root resistance factors to 'Take-all' disease. *J. Chem. Soc. Chem. Commun.*, 246-248 (1984b).
- Grayer, R. J. and Harbone, J. B. A., Survey of antifungal compounds from higher plants. *Phytochemistry*, 37, 19-42 (1994).
- Ishidate, M. and Takamura, K., Studies on the saponin of the fruit of *Camellia japonica* L. I. Isolation of Camellia-saponin and its constituents. *Yakugaku Zasshi*, 73, 347-351 (1953).
- Kazuhiro, O., Mavi, S. and Hostettmans, K., Molluscicidal and antifungal triterpenoid saponins from *Rapanea melanophloeos* leaves. *Phytochemistry*, 33, 83-86 (1993).
- Lee, E., Choi, M. Y., Park, H. J., Cha, B. C. and Cho, S. H., Chemical constituents and biological activity of *Kalopanax Cortex*. *Kor. J. Pharmacogn.*, 26, 122-129 (1995).
- Maizel, J. V., Burkhardt, H. J. and Mitchell, H. K., Avenacin, an antimicrobial substance isolated from *Avena sativa*. I. Isolation and antimicrobial activity. *Biochemistry*, 3, 424-431 (1964).
- Marston, A., Garfner, F., Dossaji, S. F. and Hostettmann, K., Fungicidal and molluscicidal saponins from *Dolichos killimandscharicus*. *Phytochemistry*, 27, 1325-1326 (1988).
- Moore, G. S. and Jaciow, D. M., Mycology from the clinical laboratory, Reston Publishing, Virginia, pp. 262-266, 1979.
- Nishino, C., Manabe, S., Enoki, N., Nagata, T., Tsushida, T. and Hamaya, E., The structure of tetrasaccharide unit of camellidins, saponins possessing antifungal activity. *J. Chem. Soc. Chem. Commun.*, 720-723 (1986).
- Ormby, O. S. and Montgomery, M., Disease of the skin. Lea & Fibiger, Philadelphia, p. 1128, 1954.
- Park, H. J., Kim, D. H., Choi, J. W., Park, J. H. and Han, Y. N., A potent anti-diabetic agent from *Kalopanax pictus*. *Arch. Pharm. Res.*, 21, 24-29 (1998).
- Sano, K., Sanada, S., Isa, Y., and Shoji, J., Studies on the constituents of the stem bark of *Kalopanax pictus* Nakai. *Chem. Pharm. Bull.*, 39, 865-870 (1991).
- Shao, C. J., Nakai, R., Ohtani, K., Xu, J. D. and Tanaka, O., Saponins from leaves of *Kalopanax septemlobus* (Thunb.) Koidz: Structures of kalopanaxaponins La, Lb and Lc. *Chem. Pharm. Bull.*, 37, 3251-3252 (1989a).
- Shao, C. J., Kasai, R., Xu, J. D. and Tanaka, O., Saponins from roots of *Kalopanax septemlobus* (Thunb.) Koidz., Ciquiu: Structures of kalopanaxaponins C, D, E and F. *Chem. Pharm. Bull.*, 37, 311-314 (1989b).
- Yamaguchi, H., Antifungal agents-Recent trends in development and progress in research of action mechanism. *Jap. J. Clin. Med.*, 49, 2176-2185 (1990).
- Yoo, C. K., The recent trends in research of new antifungal agents. *New Drug News*, 5, 14-24 (1997).